Weight Loss 

Semaglutide is an FDA-approved GLP1 agonist. Research has

demonstrated that Semaglutide supports glycemic control via improved

Insulin secretion, and weight loss and management. Other data suggests

support for reduced risk of major cardiovascular events in type 2 diabetes

patients.

​

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.

​

Semaglutide works by:

​

Reduces food intake by lowering

appetite.

• It slows food digestion in the

stomach.

• Decrease body fat percentage.

• Weight loss.

• Decreased cardiovascular outcomes

in subjects with type 2 diabetes and

cardiovascular disease.

• Lower HbA1c levels.

• Enhance the growth of β cells in the

pancreas.

​

An early study of 2,000 obese adults compared people using Semaglutide plus a diet and exercise program with people who made the same lifestyle changes without Semaglutide. After 68 weeks, half of the participants using Semaglutide lost 15% of their body weight, and nearly a third lost 20%. Participants who incorporated only lifestyle changes lost about 2.4% of their weight.

​

​